Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second phase III trial of MED2002 for the Treatment of Erectile Dysfunction (ED)

X
Trial Profile

Second phase III trial of MED2002 for the Treatment of Erectile Dysfunction (ED)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitroglycerin (Primary)
  • Indications Erectile dysfunction
  • Focus Registrational; Therapeutic Use
  • Sponsors Futura Medical
  • Most Recent Events

    • 11 Sep 2019 According to a Futura Medical media release, he protocols for this study will be the same as for "FM57" initially but will be informed by the receipt and analysis of the first Phase 3 data and adapted accordingly, if necessary, via regulatory amendments.
    • 11 Sep 2019 According to a Futura Medical media release, the company is currently undertaking pre-recruitment start-up activities in order to commence patient enrolment in H1 2020.
    • 14 Mar 2018 According to a Futura Medical media release, Interim pharmacokinetic data indicates that at least two higher strength doses of MED2002 are eligible for the planned Phase III studies (this and profile 283164) compared with the dose used in the successful Phase II study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top